215 related articles for article (PubMed ID: 20842915)
21. Secondary hyperoxalemia caused by vitamin C supplementation in regular hemodialysis patients.
Ono K
Clin Nephrol; 1986 Nov; 26(5):239-43. PubMed ID: 3802587
[TBL] [Abstract][Full Text] [Related]
22. Reduction of elevated plasma oxalic acid by pyridoxine therapy in patients on RDT.
Balcke P; Schmidt P; Zazgornik J; Kopsa H
Proc Eur Dial Transplant Assoc; 1983; 19():308-12. PubMed ID: 6878246
[TBL] [Abstract][Full Text] [Related]
23. Renal handling of middle molecules in uremic patients and in the isolated rat kidney.
Lustenberger N; Schindhelm K; Nordmeyer C; Schurek HJ; Stolte H
Artif Organs; 1981; 4 Suppl():110-4. PubMed ID: 7295076
[TBL] [Abstract][Full Text] [Related]
24. Plasma concentration and peritoneal clearance of oxalate in patients on continuous ambulatory peritoneal dialysis (CAPD).
Yamauchi A; Fujii M; Shirai D; Mikami H; Okada A; Imai E; Ando A; Orita Y; Kamada T
Clin Nephrol; 1986 Apr; 25(4):181-5. PubMed ID: 3698351
[TBL] [Abstract][Full Text] [Related]
25. Cystatin C measurement and its practical use in patients with various renal diseases.
Tian S; Kusano E; Ohara T; Tabei K; Itoh Y; Kawai T; Asano Y
Clin Nephrol; 1997 Aug; 48(2):104-8. PubMed ID: 9285147
[TBL] [Abstract][Full Text] [Related]
26. [Cardiovascular risk markers in hemodialysis].
Urso S; Milone F; Garozzo M; Cannavò ME; Biondi A; Battaglia G
G Ital Nefrol; 2004; 21 Suppl 30():S212-6. PubMed ID: 15750988
[TBL] [Abstract][Full Text] [Related]
27. An analysis of the effectiveness and benefits of peritoneal dialysis and haemodialysis using Nigerian made PD fluids.
Arogundade FA; Ishola DA; Sanusi AA; Akinsola A
Afr J Med Med Sci; 2005 Sep; 34(3):227-33. PubMed ID: 16749353
[TBL] [Abstract][Full Text] [Related]
28. [Vitamin K1 and C metabolism in uremia during hemodialysis].
Bakaev VV; Khomenko VF
Urol Nefrol (Mosk); 1991; (1):40-3. PubMed ID: 1858205
[TBL] [Abstract][Full Text] [Related]
29. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.
Brandenburg VM; Schlieper G; Heussen N; Holzmann S; Busch B; Evenepoel P; Vanholder R; Meijers B; Meert N; Fassbender WJ; Floege J; Jahnen-Dechent W; Ketteler M
Nephrol Dial Transplant; 2010 Aug; 25(8):2672-9. PubMed ID: 20172849
[TBL] [Abstract][Full Text] [Related]
30. Effect of large intake of ascorbic acid on urinary and plasma oxalic acid levels.
Tsao CS; Salimi SL
Int J Vitam Nutr Res; 1984; 54(2-3):245-9. PubMed ID: 6500850
[TBL] [Abstract][Full Text] [Related]
31. Phagocytic polymorphonuclear function in patients with progressive uremia and the effect of acute hemodialysis.
Mahajan S; Kalra OP; Asit KT; Ahuja G; Kalra V
Ren Fail; 2005; 27(4):357-60. PubMed ID: 16060119
[TBL] [Abstract][Full Text] [Related]
32. [On-line sequential hemodiafiltration (HDF-OL-S): a new therapeutic option].
Kanter J; Puerta MC; García RP; Gómez JM; Jofré R; Rodríguez PB
Nefrologia; 2008; 28(4):433-8. PubMed ID: 18662152
[TBL] [Abstract][Full Text] [Related]
33. Plasma oxalate following kidney transplantation in patients without primary hyperoxaluria.
Elgstoen KB; Johnsen LF; Woldseth B; Morkrid L; Hartmann A
Nephrol Dial Transplant; 2010 Jul; 25(7):2341-5. PubMed ID: 20167571
[TBL] [Abstract][Full Text] [Related]
34. Metabolomic profiling of uremic solutes in CKD patients.
Toyohara T; Akiyama Y; Suzuki T; Takeuchi Y; Mishima E; Tanemoto M; Momose A; Toki N; Sato H; Nakayama M; Hozawa A; Tsuji I; Ito S; Soga T; Abe T
Hypertens Res; 2010 Sep; 33(9):944-52. PubMed ID: 20613759
[TBL] [Abstract][Full Text] [Related]
35. Major factors modulating the serum oxalic acid level in hemodialysis patients.
Ogawa Y; Machida N; Jahana M; Gakiya M; Chinen Y; Oda M; Morozumi M; Sugaya K
Front Biosci; 2004 Sep; 9():2901-8. PubMed ID: 15353324
[TBL] [Abstract][Full Text] [Related]
36. Effect of hemodialysis on acid leukocyte-type ribonuclease, alkaline ribonuclease and polymorphonuclear elastase serum levels in patients with end-stage renal disease.
Naskalski JW; Kapusta M; Fedak D; Dumnicka P; Kuśnierz-Cabala B; Kuźniewski M; Sułowicz W
Nephron Clin Pract; 2009; 112(4):c248-54. PubMed ID: 19546584
[TBL] [Abstract][Full Text] [Related]
37. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
Craver L; Marco MP; Martínez I; Rue M; Borràs M; Martín ML; Sarró F; Valdivielso JM; Fernández E
Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
[TBL] [Abstract][Full Text] [Related]
38. [On-line HFR and removal of uremic toxins inducing the loss of phospholipidic asymmetry of the erythrocyte membrane].
Sirolli V; Cappelli P; Amoroso L; Di Liberato L; Muscianese P; Santarelli P; Del Rosso G; Bonomini M
G Ital Nefrol; 2004; 21 Suppl 30():S208-11. PubMed ID: 15750987
[TBL] [Abstract][Full Text] [Related]
39. Homocysteine and its determinants in nondialyzed chronic kidney disease patients.
Nerbass FB; Draibe SA; Feiten SF; Chiarello PG; Vannucchi H; Cuppari L
J Am Diet Assoc; 2006 Feb; 106(2):267-70. PubMed ID: 16442876
[TBL] [Abstract][Full Text] [Related]
40. Serum levels of beta-trace protein and its association to diuresis in haemodialysis patients.
Gerhardt T; Pöge U; Stoffel-Wagner B; Klein B; Klehr HU; Sauerbruch T; Woitas RP
Nephrol Dial Transplant; 2008 Jan; 23(1):309-14. PubMed ID: 17717031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
